James Beck, PhD, on Identifying Genetic Variants of Parkinson Disease

Video

The chief scientific officer and senior vice president of the Parkinson’s Foundation discussed mutations the Parkinson’s Foundation has identified.

“What we hope to do by our initiative is not only advanced the potential for precision medicine therapies but change the standard of care for those living with Parkinson's disease.”

The Parkinson’s Foundation is aiming to increase the genetics knowledge base of people with Parkinson disease (PD) as precision medicine and gene therapies grow in prominence and are starting to be explored and tested in more fields with the launce of PDGENEration (NCT04057794).

The Foundation believes genetic counseling and testing for people with PD needs to become part of the standard of care to enable future genetic medicine treatment or participation in clinical trials. Currently, the genetic status of many patients with PD remainsunknown since most have not been genetically tested. Participation in PDGENEration is available at-home or in-person at sites across the US to people with PD.

CGTLive spoke with James Beck, PhD, chief scientific officer and senior vice president, Parkinson’s Foundation, to learn more about the findings that PDGENEration has discovered. Neurologists seeking more information about PD GENEration can visit PDGENEration.com or email [email protected] questions about enrollment.

REFERENCE
Parkinson’s Foundation announces major expansion of PD GENErationstudy, increasing access to genetic testing and counseling across the U.S. News release. Parkinson’s Foundation. May 3, 2022. https://www.parkinson.org/about-us/press-release/Parkinsons-Foundation-expansion-PD-GENEration-study

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
© 2025 MJH Life Sciences

All rights reserved.